Skye Bioscience Inc. will get a new trial on an executive’s claims that she was fired for blowing the whistle on the former CEO’s deceptive public communications about the company’s glaucoma treatment.

A trial judge wrongly admitted evidence of a former Skye board member’s guilty plea and Securities and Exchange Commission judgment, a divided US Court of Appeals for the Ninth Circuit said Tuesday. That evidence had only slight probative value, yet was highly prejudicial to Skye, the 2-1 panel said.

The trial judge permitted the jury to impute the former board member’s misconduct to the company even though it ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.

Read Full Story: https://news.google.com/rss/articles/CBMiowFBVV95cUxPVDV0Zk5EVmFVdXFOdDlWRERM...